AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains.
AAV
gene therapy
lysosomal storage disease
mucopolysaccharidosis
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
12 Jun 2020
12 Jun 2020
Historique:
received:
13
08
2019
accepted:
02
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Patients with mucopolysaccharidosis type IIIA (MPS IIIA) lack the lysosomal enzyme sulfamidase (SGSH), which is responsible for the degradation of heparan sulfate (HS). Build-up of undegraded HS results in severe progressive neurodegeneration for which there is currently no treatment. The ability of the vector adeno-associated virus (AAV)rh.10-CAG-SGSH (LYS-SAF302) to correct disease pathology was evaluated in a mouse model for MPS IIIA. LYS-SAF302 was administered to 5-week-old MPS IIIA mice at three different doses (8.6E+08, 4.1E+10, and 9.0E+10 vector genomes [vg]/animal) injected into the caudate putamen/striatum and thalamus. LYS-SAF302 was able to dose-dependently correct or significantly reduce HS storage, secondary accumulation of GM2 and GM3 gangliosides, ubiquitin-reactive axonal spheroid lesions, lysosomal expansion, and neuroinflammation at 12 weeks and 25 weeks post-dosing. To study SGSH distribution in the brain of large animals, LYS-SAF302 was injected into the subcortical white matter of dogs (1.0E+12 or 2.0E+12 vg/animal) and cynomolgus monkeys (7.2E+11 vg/animal). Increases of SGSH enzyme activity of at least 20% above endogenous levels were detected in 78% (dogs 4 weeks after injection) and 97% (monkeys 6 weeks after injection) of the total brain volume. Taken together, these data validate intraparenchymal AAV administration as a promising method to achieve widespread enzyme distribution and correction of disease pathology in MPS IIIA.
Identifiants
pubmed: 31909089
doi: 10.1016/j.omtm.2019.12.001
pii: S2329-0501(19)30146-9
pmc: PMC6940615
doi:
Types de publication
Journal Article
Langues
eng
Pagination
174-187Informations de copyright
© 2019 The Author(s).
Références
Hum Gene Ther. 2016 Jul;27(7):478-96
pubmed: 27267688
Mol Ther Methods Clin Dev. 2014 Dec 10;1:14051
pubmed: 26052519
Mol Genet Metab. 2007 Mar;90(3):313-28
pubmed: 17166757
Hum Gene Ther. 2016 May;27(5):363-75
pubmed: 26975339
Hum Gene Ther Clin Dev. 2014 Sep;25(3):164-77
pubmed: 25144894
Mol Ther. 2005 Oct;12(4):669-79
pubmed: 16087406
Nat Biotechnol. 2016 Feb;34(2):204-9
pubmed: 26829320
Hum Gene Ther Clin Dev. 2015 Jun;26(2):113-24
pubmed: 25758611
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80
pubmed: 8134351
Mol Ther Methods Clin Dev. 2016 Jun 08;3:16036
pubmed: 27331076
Ann Neurol. 2010 Dec;68(6):876-87
pubmed: 21061399
J Neurosci Methods. 2013 Oct 30;220(1):1-8
pubmed: 23988614
Mol Genet Metab. 2006 Apr;87(4):349-58
pubmed: 16439176
Hum Gene Ther. 2012 Apr;23(4):382-9
pubmed: 22201473
J Inherit Metab Dis. 1996;19(3):278-85
pubmed: 8803769
Nat Biotechnol. 2009 Jan;27(1):59-65
pubmed: 19098898
ACS Chem Neurosci. 2019 Aug 21;10(8):3847-3858
pubmed: 31264853
Neuron. 2019 Apr 3;102(1):263
pubmed: 30946822
J Neurosci. 2002 Aug 1;22(15):6437-46
pubmed: 12151523
Hum Gene Ther Methods. 2012 Oct;23(5):324-35
pubmed: 23131032
Biochem J. 1998 Jan 1;329 ( Pt 1):145-50
pubmed: 9405287
Hum Gene Ther Clin Dev. 2014 Jun;25(2):72-84
pubmed: 24720466
Mol Ther. 2011 Jun;19(6):1058-69
pubmed: 21487395
Brain Res. 2006 Aug 9;1104(1):1-17
pubmed: 16828069
Gene Ther. 2014 Jan;21(1):28-36
pubmed: 24131981
Genes Brain Behav. 2008 Oct;7(7):740-53
pubmed: 18518922
JIMD Rep. 2016;29:59-68
pubmed: 26620043
Hum Gene Ther. 2014 Jun;25(6):506-16
pubmed: 24524415
Annu Rev Biochem. 1992;61:307-30
pubmed: 1323236
J Comp Neurol. 2004 Dec 20;480(4):415-26
pubmed: 15558784
J Neurosci. 2003 Apr 15;23(8):3302-7
pubmed: 12716937
J Inherit Metab Dis. 2014 Jan;37(1):1-12
pubmed: 23653226
Hum Gene Ther. 2018 Mar;29(3):285-298
pubmed: 29378426
Exp Neurol. 2015 Jan;263:79-90
pubmed: 25246230
EMBO Mol Med. 2013 May;5(5):675-90
pubmed: 23568409
Hum Gene Ther. 2018 Jan;29(1):15-24
pubmed: 28806897
Exp Neurol. 2017 Sep;295:243-255
pubmed: 28601604
Exp Neurol. 1999 Nov;160(1):17-27
pubmed: 10630187
Mol Ther. 2006 Mar;13(3):528-37
pubmed: 16413228
J Neurosurg. 2015 Mar;122(3):697-706
pubmed: 25397365
J Neurochem. 2016 May;137(3):409-22
pubmed: 26762778
Mol Ther. 2013 Oct;21(10):1938-49
pubmed: 23748415
Hum Gene Ther. 2019 Sep;30(9):1052-1066
pubmed: 31020862
J Clin Invest. 2013 Jul 1;123(8):3254-3271
pubmed: 23863627
Mol Ther. 2018 Mar 7;26(3):664-668
pubmed: 29428298
Curr Pharm Biotechnol. 2011 Jun;12(6):923-30
pubmed: 21235449
Hum Gene Ther. 2019 Jul;30(7):802-813
pubmed: 30808235
Mol Ther. 2014 Dec;22(12):2018-27
pubmed: 25027660
Biochem J. 2007 Apr 15;403(2):305-12
pubmed: 17206939
Am J Med Genet A. 2011 Jan;155A(1):58-68
pubmed: 21204211
Adv Drug Deliv Rev. 2012 May 15;64(7):598-604
pubmed: 22036906
Mol Ther. 2000 Jan;1(1):63-70
pubmed: 10933913
Mol Ther. 2008 Oct;16(10):1710-8
pubmed: 18714307
Hum Gene Ther Clin Dev. 2018 Mar;29(1):24-47
pubmed: 29409358
Clin Chim Acta. 1982 Aug 18;123(3):241-50
pubmed: 6811162
Annu Rev Biochem. 1991;60:257-80
pubmed: 1883197